Important Safety Information

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. To report safety concerns, please contact your local Biogen affiliate or consult your local prescribing information.

About SMA Mechanism of disease Natural History SPINRAZA^® essentials Mechanism of action Safety Posology Storage and handling Administration Technology behind SPINRAZA^®

SPINRAZA^® study programme

Overview Infantile-onset (Type I) SMA Later-onset (Type II/III) SMA Pre-symptomatic SMA Mixed SMA populations Ongoing studies Real World Evidence

Events & News

Upcoming congresses Awards Local news SPINRAZA^® patients Adults Infants & Peds Patient support programme Patient profiles

Clinical resources

Latest clinical data SCOPE tool Motor function features SPINRAZA^® MEDIA HUB Book a visit Ukraine Resources

HCP Site
Patient Site
Safety Information
Prescribing Information
Prescribing Information en Español

HCP Site
Patient Site
Safety Information
Prescribing Information
Prescribing Information en Español

Privacy Policy Terms and Conditions Cookies

This site is intended for EU healthcare professionals only.

Biogen-53476. Date of preparation: April2020.

Biogen International GmbH Neuhofstrasse 30, 6340 Baar, Switzerland.